Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Nimotuzumab and Chemotherapy for LA-SCCHN
NCT07310771Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2026
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Fujian Medical University Cancer Hospital. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07310771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07310771.